Jeanine Robinson
Family · Beckley, WVNPI 1518210012
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Procept Biorobotics Corporation at 30.8% of the total. Reporting peaked in 2024 at $4,510 and has fallen 77.3% since, to $1,025 in 2025. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $43.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$3K
- EDAP Technomed Inc$1K
- Astellas Pharma US Inc$894
- Medtronic$774
- Pfizer$552
- Axonics, Inc.$409
- plus $3K from 27 others
What the payments were for
- Travel & lodging$4,03340%
- Food & beverage$5,64856%
- Education$4034%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 22 | $3,106 |
| EDAP Technomed Inc | 2 | $1,455 |
| Astellas Pharma US Inc | 44 | $894 |
| Medtronic | 18 | $774 |
| Pfizer | 27 | $552 |
| Axonics, Inc. | 12 | $409 |
| Ambu Inc. | 7 | $356 |
| Teleflex LLC | 8 | $297 |
| Bayer | 13 | $259 |
| Organogenesis Inc. | 6 | $250 |
| AbbVie | 11 | $226 |
| Coloplast | 3 | $190 |
| Urovant Sciences Inc | 8 | $150 |
| Myriad Genetic Laboratories, Inc. | 6 | $126 |
| Urogen Pharma, Inc. | 5 | $115 |
| Endo USA, Inc. | 4 | $103 |
| Sumitomo Pharma America, Inc. | 5 | $101 |
| Olympus America Inc. | 4 | $91 |
| Seagen Inc. | 1 | $85 |
| Boston Scientific | 4 | $84 |
| Novo Nordisk | 1 | $73 |
| Myovant Sciences Inc. | 3 | $55 |
| Endo Pharmaceuticals Inc. | 3 | $53 |
| Merck | 3 | $51 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| Blue Earth Diagnostics | 2 | $41 |
| Novartis | 2 | $36 |
| Telix Pharmaceuticals | 1 | $24 |
| Convatec Inc. | 1 | $21 |
| Hollister Incorporated | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Smith+Nephew | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$2,471
- INTERSTIM$179
- Luja Coude$156
- ALTAVIVA$120
- Axonics$103
How this compares
$10,084 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 281 | $171,411 |
| ElmironPentosan Polysulfate Sodium | 17 | $16,396 |
| GemtesaVibegron | 11 | $12,721 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 157 | $3,655 |
| Trospium Chloride | 90 | $3,586 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 54 | $2,866 |
| Tamsulosin Hcl | 319 | $2,409 |
| Potassium Citrate ErPotassium Citrate | 49 | $1,816 |
| Solifenacin Succinate | 74 | $1,807 |
| Trimethoprim | 20 | $1,427 |
| Oxybutynin Chloride ErOxybutynin Chloride | 47 | $661 |
| Cephalexin | 97 | $511 |
| Finasteride | 46 | $405 |
| Oxybutynin Chloride | 27 | $258 |
| Testosterone Cypionate | 15 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $894 | $171,411281 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $101 | $12,72111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Beckley
- Erica ShrewsburyBeckley$20K
- Melissa RamseyBeckley$12K
- Dana FrobleBeckley$10K
- Rosalind BerryBeckley$9K
- Leslie LillyBeckley$8K
- Jennifer WhaleyBeckley$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.